排序方式: 共有44条查询结果,搜索用时 0 毫秒
41.
Faber E Friedecký D Mičová K Rožmanová S Divoká M Jarošová M Indrák K Adam T 《Annals of hematology》2012,91(6):923-929
Association of trough imatinib plasma levels (IPL) with cytogenetic or molecular response to treatment in patients with chronic
myeloid leukemia (CML) was repeatedly reported. We analyzed their value in the routine clinical setting in 131 patients with
chronic phase CML in whom imatinib was applied as first- or second-line treatment. A total of 1,118 measurements were obtained
by ultra-performance liquid chromatography–tandem mass spectrometry assay in patients treated with daily dose of imatinib
ranging from 100 to 800 mg. Samples were obtained from 1 to 96 h after drug ingestion. High inter (36%) and intraindividual
variability (9–33%) of IPL was observed. For analysis of correlation of IPL with treatment response, two sets of samples were
selected according to the European LeukemiaNet (ELN) criteria. The first set consisted of 241 samples taken 24 ± 2 h after
dosing in 54 patients, and the second one consisted of 329 samples taken 24 ± 4 h after imatinib ingestion in 84 patients.
In both sets, only patients treated with 400 mg imatinib once daily for at least 18 months were included. From multiple measurements
in individual patients, mean IPL were used. In both sets, we were not able to demonstrate a statistically significant correlation
between IPL and response to treatment according to the ELN. We believe that this was due to the differences in patients’ compliance,
leukemia biology, and other variables that are difficult to eliminate in the routine clinical practice. The use of IPL for
prognostic estimation in CML treatment outside the clinical trials is probably limited. 相似文献
42.
Faber E Mužík J Koza V Demečková E Voglová J Demitrovičová L Chudej J Markuljak I Cmunt E Kozák T Tóthová E Jarošová M Dušek L Indrák K 《European journal of haematology》2011,87(2):157-168
Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Data reporting was retrospective in 2000–2004 and prospective from 2005 on. A total of 661 patients [301 women and 360 men; median age 51 (range, 15–83)] with Ph + CML were registered. The median follow‐up was 46.1 months (0–122.2). Results: Most patients were treated with first‐ (379; 57.3%) or second‐line (193; 29.2%) imatinib; some of the patients underwent allogeneic hematopoietic stem cell transplantation (AHSCT) (83; 12.6%), but 6.1% were treated with other modalities [40 patients; median age 66 (range, 32–83)]. The probability of overall survival (OS) at 5 years, according to Kaplan and Meier, was 88.9%, 77.5% and 68.7% for chronic‐phase patients treated with first‐line imatinib, second‐line imatinib and first‐line AHSCT, respectively, but only 25.2% for patients receiving other modalities. The OS was dependent on the disease phase and Sokal, Hasford and European group for blood and marrow transplantation (EBMT) risk scores (P < 0.001; each). Only 46.2% of deaths in patients treated with other modalities were attributable to CML. Elderly patients over 65 years achieved similar response rates and progression‐free survival to the younger ones. There was a trend for inferior results of AHSCT performed after the failure of imatinib (P = 0.075), probably as a result of differences in EBMT risk scores (P < 0.001). Conclusions: The ability to achieve results comparable to those of previous clinical studies in our CML cohort was influenced by centralised care. Decisions not to initiate imatinib or to delay AHSCT may have a negative impact on OS, but comorbidities may limit the treatment potential of imatinib in the elderly. 相似文献
43.
44.